Moderna, after monumental commercial debut, forecasts $22B in COVID shot sales this yearnews2022-02-24T13:43:43+00:00February 24th, 2022|Fierce Pharma|
Regeneron, Bayer’s Eylea ‘to remain king’ as analysts see ‘tepid’ response to biosimilar threatsnews2022-02-24T13:30:37+00:00February 24th, 2022|Fierce Pharma|
Sanofi presses CDC experts to back its high-dose Fluzone shot for older adultsnews2022-02-24T12:13:19+00:00February 24th, 2022|Fierce Pharma|
Alkermes’ Lybalvi launch serves as a new litmus test for mental illness marketingnews2022-02-24T10:48:59+00:00February 24th, 2022|Fierce Pharma|
Lundbeck teams up with Mental Health America to tackle the other COVID crisisnews2022-02-24T09:39:40+00:00February 24th, 2022|Fierce Pharma|
‘Major blunder:’ Ex-staffers blast Bristol Myers Squibb’s handling of Breyanzi approval in latest CVR lawsuit updatenews2022-02-23T16:57:12+00:00February 23rd, 2022|Fierce Pharma|
Novavax begins delivery of its long-delayed COVID-19 vaccine in Europenews2022-02-23T16:14:11+00:00February 23rd, 2022|Fierce Pharma|
Gearing up for anemia market-grab against GSK—and maybe AZ—Akebia expands Vifor pact with $85M for key launchnews2022-02-23T15:42:32+00:00February 23rd, 2022|Fierce Pharma|
Intellia leases new facility to produce CRISPR-based therapiesnews2022-02-23T15:40:58+00:00February 23rd, 2022|Fierce Pharma|
Johnson & Johnson, Moderna set to face shareholder votes on vaccine pricing strategy, manufacturing tech sharingnews2022-02-23T15:27:03+00:00February 23rd, 2022|Fierce Pharma|
